Harmony Biosciences (HRMY) Revenue & Revenue Breakdown
Harmony Biosciences Revenue Highlights
Latest Revenue (Y)
$714.73M
Latest Revenue (Q)
$184.73M
Main Geography (Y)
United States
Harmony Biosciences Revenue by Period
Harmony Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $714.73M | 22.80% |
| 2023-12-31 | $582.02M | 32.93% |
| 2022-12-31 | $437.86M | 43.35% |
| 2021-12-31 | $305.44M | 91.21% |
| 2020-12-31 | $159.74M | 2564.59% |
| 2019-12-31 | $6.00M | 100.00% |
| 2018-12-31 | - | - |
Harmony Biosciences generated $714.73M in revenue during NA 2024, up 22.80% compared to the previous quarter, and up 11922.17% compared to the same period a year ago.
Harmony Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $184.73M | -8.21% |
| 2024-12-31 | $201.27M | 8.19% |
| 2024-09-30 | $186.04M | 7.65% |
| 2024-06-30 | $172.81M | 11.77% |
| 2024-03-31 | $154.62M | -8.19% |
| 2023-12-31 | $168.41M | 5.08% |
| 2023-09-30 | $160.27M | 19.41% |
| 2023-06-30 | $134.22M | 12.67% |
| 2023-03-31 | $119.13M | -7.16% |
| 2022-12-31 | $128.31M | 9.47% |
| 2022-09-30 | $117.21M | 9.51% |
| 2022-06-30 | $107.03M | 25.45% |
| 2022-03-31 | $85.31M | -6.47% |
| 2021-12-31 | $91.21M | 12.98% |
| 2021-09-30 | $80.73M | 9.36% |
| 2021-06-30 | $73.82M | 23.71% |
| 2021-03-31 | $59.67M | 6.02% |
| 2020-12-31 | $56.29M | 23.41% |
| 2020-09-30 | $45.61M | 20.01% |
| 2020-06-30 | $38.01M | 91.56% |
| 2020-03-31 | $19.84M | 230.94% |
| 2019-12-31 | $6.00M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Harmony Biosciences generated $184.73M in revenue during Q1 2025, up -8.21% compared to the previous quarter, and up 109.69% compared to the same period a year ago.
Harmony Biosciences Revenue Breakdown
Harmony Biosciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| United States | $500.00M | $500.00M |
Latest
Harmony Biosciences's latest annual revenue breakdown by geography, as of Dec 23: United States (100.00%).
Quarterly Revenue by Country
| Country | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|
| United States | - | - | $500.00M | $500.00M | $500.00M |
Latest
Harmony Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $714.73M | $184.73M |
| TVTX | Travere Therapeutics | $233.18M | $81.73M |
| GOSS | Gossamer Bio | $114.70M | $9.89M |
| FENC | Fennec Pharmaceuticals | $47.54M | $7.92M |
| VRNA | Verona Pharma | $42.28M | $76.26M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
| JANX | Janux Therapeutics | $10.59M | - |
| KRON | Kronos Bio | $9.85M | $2.27M |
| IDYA | IDEAYA Biosciences | $7.00M | $7.00M |
| KROS | Keros Therapeutics | $3.55M | $3.04M |
| LYRA | Lyra Therapeutics | $1.53M | $209.00K |
| GPCR | Structure Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | $170.64M |
| VTYX | Ventyx Biosciences | - | - |
| NUVL | Nuvalent | - | - |
| VRDN | Viridian Therapeutics | - | $72.00K |
| RVMD | Revolution Medicines | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| NVCT | Nuvectis Pharma | - | - |
| INZY | Inozyme Pharma | - | - |
| PLRX | Pliant Therapeutics | - | - |